Premium
Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?
Author(s) -
MATHEW PAUL,
AHMANN GREGORY J.,
WITZIG THOMAS E.,
ROCHE PATRICK C.,
KYLE ROBERT A.,
GREIPP PHILIP R.
Publication year - 1995
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1995.tb05175.x
Subject(s) - monoclonal gammopathy of undetermined significance , multiple myeloma , medicine , monoclonal gammopathy , plasma cell , expression (computer science) , pathology , monoclonal , immunology , monoclonal antibody , antibody , computer science , programming language
Summary. Prior studies have suggested that loss of plasma cell CD 5 6 expression in multiple myeloma defines a unique patient subset and that CD56 expression reliably discriminates between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). We conducted a study of 68 untreated patients with MM from a single institution to define the clinicopathological correlates of CD56 expression. We find CD56 expression in 55% of MM. Lack of CD56 expression does not define a unique clinicopathological or prognostic entity in MM. Strong CD 5 6 expression can also be found in MGUS and does not help to distinguish from MM.